1672 — Ascletis Pharma Cashflow Statement
0.000.00%
- HK$6.05bn
- HK$3.98bn
- CNY1.28m
Annual cashflow statement for Ascletis Pharma, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -209 | -199 | -315 | -145 | — |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 29.1 | 8.31 | 82.8 | -132 | — |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 68 | 14.2 | 59.4 | 114 | -342 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -84.9 | -147 | -142 | -144 | -342 |
Capital Expenditures | -39 | -7.2 | -14.4 | -19.2 | — |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 171 | -267 | -1,283 | 169 | 979 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Sale of Intangible Assets | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 132 | -274 | -1,297 | 150 | 979 |
Financing Cash Flow Items | — | -0.125 | -0.157 | -0.144 | -104 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -21.7 | -31.1 | -1.42 | -81.5 | -104 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -84.5 | -483 | -1,324 | -73.7 | 534 |